Study: Why even targeted lung cancer therapies eventually fail

Even when patients are treated with targeted cancer therapies, many lung cancer patients suffer a recurrence. Researchers at Cold Spring Harbor Laboratory wanted to uncover how some cancers escape the power of targeted treatment. Their work was published in the journal eLife this week. The team of scientists, lead by Raffaella Sordella, found that a tiny subset of cells in or around a cancerous tumor can change over time and become the seeds of a killer relapse. Get the full story at our sister site, Drug Delivery Business News.   The post Study: Why even targeted lung cancer therapies eventually fail appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Oncology Research & Development Respiratory Cold Spring Harbor Laboratory Source Type: news

Related Links:

Abstract Sorcin (Soluble resistance related calcium binding protein) is a small soluble penta EF family (PEF) of calcium (Ca2+) binding protein (22,000 Da). It has been reported to play crucial roles in the regulation of calcium homeostasis, apoptosis, vesicle trafficking, cancer development, and multidrug resistance (MDR). Overexpression of sorcin has been reported to be associated with different cancers such as breast cancer, colorectal cancer, gastric cancer, leukemia, lung cancer, nasopharyngeal cancer, ovarian cancer, etc. Essentially, expression of sorcin has been found to be elevated in cancer cells as comp...
Source: Translational Oncology - Category: Cancer & Oncology Authors: Tags: Transl Oncol Source Type: research
Abstract Although epidermal growth factor receptor (EGFR) inhibitors have been used to treat non-small cell lung cancer (NSCLC) for decades with great success in patients with EGFR mutations, acquired-resistance inevitably occurs after long-term exposure to the treatment of EGFR inhibitors. Glycolysis is a predominant process for most cancer cells to utilize glucose, which referred to as the Warburg Effect. Targeting critical enzymes, such as pyruvate dehydrogenase kinase 1 (PDK1) that inversely regulating the process of glycolysis could be a promising approach to work alone or in combination with other treatments...
Source: European Journal of Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Eur J Pharmacol Source Type: research
In conclusion, our novel formulation destabilized H358 cells by using its acidic tumor microenvironment, thereby regulating cell apoptosis, proliferation, and metastatic properties. PMID: 30184773 [PubMed - in process]
Source: Appl Human Sci - Category: Physiology Authors: Tags: Mater Sci Eng C Mater Biol Appl Source Type: research
Abstract Non-small cell lung cancer (NSCLC) has a high mortality rate worldwide. Various treatments strategies have been used against NSCLC including individualized chemotherapies, but innate or acquired cancer cell drug resistance remains a major obstacle. Recent studies revealed that the Kelch-like ECH associated protein 1/Nuclear factor erythroid 2-related factor 2 (Keap1/Nrf2) pathway is intimately involved in cancer progression and chemoresistance. Thus, antagonizing Nrf2 would seem to be a viable strategy in cancer therapy. In the present study a traditional Chinese medicine, triptolide, was identified that ...
Source: Toxicology and Applied Pharmacology - Category: Toxicology Authors: Tags: Toxicol Appl Pharmacol Source Type: research
ConclusionPotentiation of the action of Gnb when co administered with Cap NPs can be a promising breakthrough for developing safe, effective and targeted delivery for lung carcinoma therapy.Graphical abstract
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
In this study, MSCs were used as lung targeted delivery vehicles by loading nanoparticles that carrying anti-cancer drug. The high efficiency of lung targeting of MSCs was validated in different animals, and this system efficiently inhibited primary lung tumor growth with lower dose of anti-cancer drug. Production Note: KrasG12Dshould beKrasG12D
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Abstract Anoikis-resistance is a critical step in cancer progression, especially during the process of metastasis. During this phase, the cancer phenotype that causes cell survival in detachment conditions, drug resistance, and epithelial-to-mesenchymal transition (EMT) is altered. Inhibition of anoikis-resistance can potentially be the molecular target in cancer therapy. Alpha-mangostin, an active compound in Garcinia mangostana, has been reported for its cell-death induction and its chemosensitizing and anti-metastatic properties in many cancer cell types, such as ovarian cancer, lung cancer, and hepatocellular ...
Source: Toxicology in Vitro - Category: Toxicology Authors: Tags: Toxicol In Vitro Source Type: research
Abstract Lung cancer is a highly invasive and prevalent disease with ineffective first-line treatment and remains the leading cause of cancer death in men and women. Despite the improvements in diagnosis and therapy, the prognosis and outcome of lung cancer patients is still poor. This could be associated with the lack of effective first-line oncology drugs, formation of resistant tumors and non-optimal administration route. Therefore, the repurposing of existing drugs currently used for different indications and the introduction of a different method of drug administration could be investigated as an alternative ...
Source: Advanced Drug Delivery Reviews - Category: Drugs & Pharmacology Authors: Tags: Adv Drug Deliv Rev Source Type: research
Authors: Vougiouklakis T, Saloura V, Park JH, Takamatsu N, Miyamoto T, Nakamura Y, Matsuo Y Abstract Protein methyltransferase SUV39H2 was reported to methylate histone H2AX at lysine 134 and enhance the formation of phosphorylated H2AX (γ-H2AX), which causes chemoresistance of cancer cells. We found that a series of imidazo[1,2-a]pyridine compounds that we synthesized could inhibit SUV39H2 methyltransferase activity. One of the potent compounds, OTS193320, was further analyzed in in vitro studies. The compound decreased global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggered ap...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
New lung cancer therapies are constantly being developed and approved. Indeed, the new treatments on the market have rendered chemotherapy increasingly redundant. Matti Aapro, MD, of the Clinique de G... Author: VJOncology Added: 08/29/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Cancer Therapy | Laboratory Medicine | Lung Cancer | Respiratory Medicine | Study